Duke University Medical Center, Durham, NC, USA.
CLION - CAM Group, Salvador, Brazil.
Curr Treat Options Oncol. 2019 Mar 28;20(4):35. doi: 10.1007/s11864-019-0634-5.
Immunotherapy has become one of the greatest advances in medical oncology over the last century; however, the optimal application for the treatment of breast cancer remains an active area of investigation. Modern immunotherapy strategies augment the immune system and ideally, permit durable tumor-specific immune memory. In fact, several monoclonal antibodies that mediate the immune checkpoint receptors have provided the most clinically meaningful improvement for breast cancer patients to date, particularly for the triple negative subtype. Checkpoint blockade as monotherapy has demonstrated some encouraging results, although some combination strategies appear to augment those responses and may be particularly effective when administered earlier in the course of disease. For example, the combination of atezolizumab and nab-paclitaxel as first-line therapy for metastatic triple negative breast cancer demonstrated significant improvements in progression-free survival when compared with chemotherapy alone. Herein, we review the data for immune therapy in breast cancer and highlight promising future directions.
免疫疗法在过去一个世纪中成为医学肿瘤学的最大进展之一；然而，治疗乳腺癌的最佳应用仍然是一个活跃的研究领域。现代免疫疗法策略增强了免疫系统，理想情况下，允许持久的肿瘤特异性免疫记忆。事实上，几种介导免疫检查点受体的单克隆抗体为乳腺癌患者提供了迄今为止最有临床意义的改善，特别是对于三阴性亚型。作为单药治疗的检查点阻断已经显示出一些令人鼓舞的结果，尽管一些联合策略似乎增强了这些反应，并且在疾病早期给药时可能特别有效。例如，atezolizumab 和 nab-紫杉醇联合作为转移性三阴性乳腺癌的一线治疗，与单独化疗相比，无进展生存期显著改善。在此，我们综述了乳腺癌免疫治疗的数据，并强调了有前途的未来方向。
